Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jazz Pharmaceuticals plc

http://jazzpharma.com

Latest From Jazz Pharmaceuticals plc

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Prescription Marijuana? FDA Rescheduling Memo Sets Stage To Test Whether There’s A Viable Market

Rise in state-legalized marijuana helped pushed FDA to recommend more lenient regulation of the substance, easing pathway to prescription drug approval, but those same state markets may pose a challenge for commercialization of an Rx botanical if DEA follows through on rescheduling.

FDA United States

Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win

The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.

Clinical Trials Business Strategies

Resilient Redx Inks Jazz KRAS Pact

The UK biotech has teamed up again with Jazz, banking a $10m upfront fee that will help towards advancing its wholly owned ROCK inhibitor program for fibrosis indications.

Deals Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Manufacturing Organization
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Alizé Pharma II
    • Azur Pharma Public Limited Company
    • Cavion, Inc.
    • Cavion LLC (Tau Therapeutics LLC
    • Xdynia LLC)
    • Celator Pharmaceuticals, Inc.
    • Gentium S.p.A.
    • GW Pharmaceuticals plc
    • Jazz Pharmaceuticals Ireland Limited
    • Orphan Medical, Inc.
UsernamePublicRestriction

Register